Infant Bacterial Therapeutics AB - Class B

OSTO:IBT B (Sweden)   Class B
kr 97.80 (-1.21%) May 15
At Loss
P/B:
4.75
Market Cap:
kr 1.32B ($ 123.74M)
Enterprise V:
kr 1.01B ($ 94.66M)
Volume:
18.23K
Avg Vol (2M):
5.12K
Also Trade In:
Volume:
18.23K
At Loss
Avg Vol (2M):
5.12K

Business Description

Description
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118 and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.
Name Current Vs Industry Vs History
Cash-To-Debt No Debt
Equity-to-Asset 0.8
Interest Coverage No Debt
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 78.15
9-Day RSI 74.58
14-Day RSI 70.42
6-1 Month Momentum % -7.93
12-1 Month Momentum % 81.74

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 4.74
Quick Ratio 4.74
Cash Ratio 4.33

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -6.3
Shareholder Yield % -8.07
Name Current Vs Industry Vs History
ROE % -42.28
ROA % -36.94
ROIC % -477.43
ROCE % -42.28

Financials (Next Earnings Date:2024-08-28)

OSTO:IBT B's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Infant Bacterial Therapeutics AB Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil kr)
EPS (TTM) (kr) -10.03
Beta 0
Volatility % 74.89
14-Day RSI 70.42
14-Day ATR (kr) 4.5021
20-Day SMA (kr) 89.14
12-1 Month Momentum % 81.74
52-Week Range (kr) 42.5 - 106.5
Shares Outstanding (Mil) 13.47

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Infant Bacterial Therapeutics AB Filings

Filing Date Document Date Form
No Filing Data

Infant Bacterial Therapeutics AB Stock Events

Financials Calendars
Event Date Price(kr)
No Event Data

Infant Bacterial Therapeutics AB Frequently Asked Questions

What is Infant Bacterial Therapeutics AB(OSTO:IBT B)'s stock price today?
The current price of OSTO:IBT B is kr97.80. The 52 week high of OSTO:IBT B is kr106.50 and 52 week low is kr42.50.
When is next earnings date of Infant Bacterial Therapeutics AB(OSTO:IBT B)?
The next earnings date of Infant Bacterial Therapeutics AB(OSTO:IBT B) is 2024-08-28.
Does Infant Bacterial Therapeutics AB(OSTO:IBT B) pay dividends? If so, how much?
Infant Bacterial Therapeutics AB(OSTO:IBT B) does not pay dividend.

Press Release

Subject Date
No Press Release